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Abstract
Background The aim of the study was to identify factors
significantly associated with the occurrence of unintended
treatment interruptions in adjuvant breast cancer radiother-
apy.
Patients and methods Patients treated with postoperative
radiotherapy of the breast or chest wall between March
2014 and August 2016 were evaluated. The radiotherapy
regimens and techniques applied were either conventional
fractionation (CF; 28 daily fractions of 1.8 Gy or 25 frac-
tions of 2.0 Gy) or hypofractionation (HF; 15 daily fractions
of 2.67 Gy) with inverse planned intensity-modulated radio-
therapy (IMRT) or three-dimensional planned conformal ra-
diotherapy (3DCRT). Logistic regression analysis was used
to identify factors associated with noncompliance. Non-
compliance was defined as the missing of at least one sched-
uled radiotherapy fraction.
Results In all, 19 of 140 (13.6%) patients treated with HF
and 39 of 146 (26.7%) treated with CF experienced treat-
ment interruptions. Of 23 factors tested, the fractionation
regimen emerged as the only independent significant prog-
nostic factor for noncompliance on multivariate analysis
(CF; p = 0.007; odds ratio, 2.3; 95% confidence interval,
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1.3–4.2). No statistically significant differences concerning
the reasons for treatment interruptions could be detected
between patients treated with CF or HF.
Conclusion HF is significantly associated with a better pa-
tient compliance with the prescribed radiotherapy schedule
compared with CF. The data suggest that this finding is ba-
sically related to the shorter overall treatment time of HF.
Keywords Breast neoplasms · Radiotherapy · Dose
hypofractionation · Radiation injuries · Risk factors
Signifikant bessere Patientencompliance bei
hypofraktionierter im Vergleich zu konventionell
fraktionierter adjuvanter Strahlentherapie des
Mammakarzinoms
Ergebnisse einer unizentrischen retrospektiven Studie
Zusammenfassung
Hintergrund Ziel der Untersuchung war es, Faktoren zu
identifizieren, die mit ungeplanten Behandlungsunterbre-
chungen bei der adjuvanten Strahlentherapie des Mamma-
karzinoms assoziiert sind.
Methoden und Patienten Es wurden Patienten untersucht,
die eine adjuvante Strahlentherapie der Mamma oder Brust-
wand zwischen März 2014 und August 2016 erhielten.
Zur Anwendung kamen als Fraktionierungsprotokoll und
strahlentherapeutische Technik eine konventionell fraktio-
nierte (CF; 28 Fraktionen mit 1,80 Gy oder 25 Fraktionen
mit 2,00 Gy) oder eine hypofraktionierte Strahlentherapie
(HF; 15 Fraktionen mit 2,67 Gy), eine intensitätsmodulier-
te (IMRT) oder dreidimensional geplante konformale Strah-
lentherapie (3DCRT). Mögliche mit Noncompliance asso-
ziierte Faktoren wurden mittels logistischer Regressions-
analyse untersucht. Noncompliance wurde als gegeben be-
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trachtet bei dem Ausfall mindestens einer geplanten Strah-
lentherapiefraktion.
Ergebnisse Bei 19 von 140 (13,6 %) Patienten mit HF und
39 von 146 (26,7 %), die mit CF behandelt wurden, tra-
ten ungeplante Behandlungsunterbrechungen auf. Von 23
untersuchten Faktoren ging als einziger unabhängiger sig-
nifikanter Faktor für Noncompliance das Fraktionierungs-
protokoll aus der multivariaten Analyse hervor (CF; p =
0,007; Odds Ratio: 2,3; 95%-Konfidenzintervall: 1,3–4,2).
Bezüglich der Ursachen ungeplanter Behandlungsunterbre-
chungen konnte kein statistisch signifikanter Unterschied
festgestellt werden.
Schlussfolgerung Die HF ist signifikant mit einer besseren
Patientencompliance im Vergleich zur CF assoziiert. Die
Daten legen nahe, dass diese Assoziation hauptsächlich auf
die kürzere Gesamtbehandlungszeit der HF zurückzuführen
ist.
Schlüsselwörter Neoplasien der Mamma ·
Strahlentherapie · Hypofraktionierung · Strahlenbedingte
Nebenwirkungen · Risikofaktoren
Background
Unintended treatment interruptions may lead to a prolon-
gation of the prescribed overall treatment time. For radio-
therapy with curative intent, prolongation of the prescribed
overall treatment time has been linked to inferior clinical
outcomes [1–3]. This association appears to be consistent
across many disease sites including head and neck can-
cer, cervical cancer, lung cancer, breast cancer, and other
cancers [4, 5]. Prospective and retrospective studies have
shown that treatment prolongation can increase the risk of
local recurrence by up to 2% per day for certain malignan-
cies [5].
The association between prolongation of the prescribed
overall treatment time and inferior clinical outcomes has
been explained with an accelerated repopulation of tumor
clonogens, which can occur after treatment initiation [6].
It has also been reported that noncompliance may serve as
a behavioral biomarker for other risk factors that contribute
to poor outcomes, such as noncompliance with other impor-
tant clinician visits and procedures, lack of social support,
and mood disorders [4].
In this study, we analyzed the compliance to the pre-
scribed radiotherapy schedule of breast cancer patients
treated with postoperative radiotherapy of the whole breast
or chest wall. The goal of the study was to identify factors
significantly associated with the occurrence of treatment
interruptions.
Patients and methods
Data collection and patient selection
The electronic patient files of 286 consecutive unselected
patients treated with adjuvant breast cancer radiotherapy be-
tween March 2014 and August 2016 were reviewed. Eligi-
bility criteria for the analysis were (a) histologically proven
diagnosis of breast cancer or carcinoma in situ and (b) treat-
ment with adjuvant postoperative radiotherapy after breast-
conserving surgery or mastectomy. Exclusion criteria were
bilateral breast cancer or history of previous radiotherapy
of the breast or chest wall.
Patients were treated with either conventional fraction-
ation (CF; 28 daily fractions of 1.8 Gy or 25 fractions
of 2.0 Gy) or hypofractionation (HF; 15 daily fractions
of 2.67 Gy). Where indicated, an electron boost was ap-
plied (five or eight daily fractions of 2.0 Gy). Radiotherapy
fractions were scheduled once per day and five times per
week. Patients who missed radiotherapy fractions were of-
fered to be treated on weekends in order not to exceed
the prescribed overall treatment time. The radiation tech-
niques used were inverse planned intensity-modulated ra-
diotherapy (IMRT) or three-dimensional planned conformal
radiotherapy using wedge compensation (3DCRT). The pa-
tients were thoroughly informed about the pros and cons
of the two fractionation regimens and radiation techniques,
and the treatment decision was mainly based on patient
preference. Patients not covered, or not fully covered, by
medical insurance tended to opt for 3DCRT for financial
reasons. Patients with personal commitments limiting the
overall treatment time or patients living far away from the
radiotherapy facility tended to opt for HF.
The acute radiation reactions and reasons for treatment
interruptions were documented prospectively in the Lo-
cal Area Network Therapy Information System “Lantis”
(Siemens Healthcare, Germany). The acute radiation reac-
tions were assessed once weekly during radiotherapy and
6 weeks after radiotherapy by two observers using the Com-
mon Terminology Criteria for Adverse Events (CTCAE
v4.03). The two observers were not involved in the sta-
tistical analysis of the study, and a table with all weekly
assessments was included in the “End of Treatment Re-
port” of all patients. The maximum acute radiation reaction
observed during the full course of the radiotherapy (in-
cluding the boost to the tumor bed if applied) was used
for the statistical analysis. Treatment interruptions were de-
fined as missing at least one of the scheduled daily radio-
therapy fractions. The reasons for treatment interruptions
were categorized into “public holidays,” “patient unwill-
ingness,” “machine breakdown,” “radiation reactions,” and
“unspecified,” and documented prospectively together with
the length of the treatment interruption.
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The study was approved by the local institutional ethics
committee and conducted in accordance with the Helsinki
Declaration in its current version.
Treatment planning and radiation techniques
The treatment planning and radiation techniques used for
this study have been described in detail elsewhere [7–9]. In
short, a non-contrast computed tomography (CT) simula-
tion with a slice thickness of 5 mm was performed with the
patient in the supine position. The planning target volume
(PTV) of the whole breast or chest wall was defined accord-
ing to the recommendations of the breast cancer atlas for
radiation therapy planning consensus definitions of the Ra-
diation Therapy Oncology Group (RTOG) [10]. The IMRT
and 3DCRT plans were generated using the treatment plan-
ning system XIO 4.4 (CMS, Inc., St. Louis, Mo.). The dose
to the PTV was prescribed according to the International
Commission on Radiation Units and Measurement (ICRU)
Reports 50 and 62 recommendations. Two Siemens Oncor
Anvantgarde linear accelerators with a 160 MLC Multi-
leaf Collimator were used for the treatment. Daily online
verification and correction of the patient positioning error
prior to radiotherapy were performed for all patients us-
ing orthogonal megavoltage electronic portal images [11].
No respiratory gating [12–14], integrated boost [15, 16],
or partial breast irradiation [17] techniques were applied
in this study. Two tangential semi-opposed beams, physical
wedges (usually 15° or 30°), a 160 MLC Multileaf Col-
limator and 6 MV photons were used for the IMRT and
3DCRT plans. Occasionally a mixed-beam technique using
6 MV and 15 MV photons was used for the 3DCRT plans.
Inverse treatment planning and a step-and-shoot technique
were used for all IMRT plans. Tissue inhomogeneities were
considered in the treatment planning optimization process,
and the dose calculation algorithm used was “Superposi-
tion.” A few patients with left-sided breast cancer and un-
favorable thoracic geometry were treated with seven-field
IMRT in order to reduce the high-dose region to the heart
[18].
Statistical analysis
Differences between patient groups stratified by the occur-
rence of treatment interruptions (Table 1) or by the fraction-
ation regimen (Table 3) were assessed using the chi-square
test or t test where appropriate. To assess the association
of multiple factors with the occurrence of treatment in-
terruptions, a univariate and multivariate logistic regression
analysis was performed. The factors tested in the logistic re-
gression analysis are listed in Table 2. The model selection
of the multivariate analysis was performed by a backward
stepwise strategy. All tests were two-sided, and a p value
of 0.05 was considered significant.
Results
In total, 58 of 286 (20.3%) patients experienced treatment
interruptions. The patient, disease, and treatment character-
istics of the study population stratified by the occurrence
of treatment interruptions are demonstrated in Table 1. As
expected, the mean age of the study population was con-
siderably lower compared with reports from Europe or the
United States, most likely due to the young age structure of
the general population [19].
On univariate analysis, three of 23 tested factors were
significantly associated with a higher risk of treatment inter-
ruptions (Table 2). All three factors were related to longer
treatment courses (CF, number of radiotherapy fractions
≥29, boost to the tumor bed). In total, 19 of 140 (13.6%)
patients treated with HF and 39 of 146 (26.7%) treated
with CF had treatment interruptions. On multivariate anal-
ysis, the only remaining independent significant prognostic
factor was the fractionation regimen: CF vs. HF; p = 0.007;
odds ratio (95% confidence interval) 2.3 (1.3, 4.2).
Concerning the reasons for treatment interruptions, no
statistically significant differences were detected between
the patients treated with CF and HF (Table 3). However,
treatment interruptions were on average longer for patients
treated with CF (3.2 days vs. 2.3 days; p = 0.02; Table 3).
In accordance with our departmental policy, treatment in-
terruptions were compensated by treating the corresponding
patients on weekends within the prescribed overall treat-
ment time. After compensation for treatment interruptions,
eventually 41.4% of the patients with treatment interrup-
tions completed their treatment within the prescribed over-
all treatment time, corresponding to 88.1% of the total study
population. The remaining patients experienced a prolon-
gation of the prescribed overall treatment time of 1–5 days
(Table 3).
Discussion
Our study shows that a significant proportion of our patients
experienced unintended treatment interruptions (20.3%).
The compliance to the prescribed radiotherapy schedule
was significantly better with HF than with CF (patients
with treatment interruptions; 13.6% vs. 26.7%). The data
suggest that the better compliance was basically related
to the shorter overall treatment time of HF (3–4 weeks)
compared with CF (5–6.5 weeks).
Several randomized trials have shown that HF is equally
effective in long-term disease control and late radiation ef-
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Table 1 Patient, disease, and treatment characteristics stratified by occurrence of treatment interruptions
Characteristics Total Treatment interruptions p
Yes No
n % n % n %
Patients 286 100 58 20.3 228 79.7 –
Country of origin Middle East 208 72.7 42 72.4 166 72.8 0.18
Asia 42 14.7 7 12.1 35 15.4 –
Africa 25 8.7 4 6.9 21 9.2 –
Europe/USA 11 3.8 5 8.6 6 2.6 –
Age at diagnosis (years) Mean (SD) 48 (9.6) 48 (8.9) 49 (9.8) 0.65a
Body mass index <25 47 16.5 12 20.7 35 15.4 0.57
25–29 76 26.7 16 27.6 60 26.4 –
≥30 162 56.8 30 51.7 132 58.1 –
Menopausal status Premenopausal 143 50.0 31 53.4 112 49.1 0.56
Postmenopausal 143 50.0 27 46.6 116 50.9 –
Marital status Married 270 94.4 57 98.3 213 93.4 0.15
Single 16 5.6 1 1.7 15 6.6 –
Financial status Medical insurance 163 57.0 30 51.7 133 58.3 0.36
Cash 123 43.0 28 48.3 95 41.7 –
Distance from home to treatment facility
(km)
50 183 64.0 39 67.2 144 63.2 0.65
51–100 62 21.7 10 17.2 52 22.8 –
>100 41 14.3 9 15.5 32 14.0 –
Pathohistology Invasive ductal cancer 264 92.3 53 91.4 211 92.5 0.83
Invasive lobular can-
cer
15 5.2 4 6.9 11 4.8 –
DCIS 5 1.7 1 1.7 4 1.8 –
Other 2 0.7 0 0.0 2 0.9 –
Grading G1 22 7.7 6 10.3 16 7.0 0.31
G2 91 31.8 20 34.5 71 31.1 –
G3 146 51.0 24 41.4 122 53.5 –
Not reported 27 9.4 8 13.8 19 8.3 –
T classification pTis 6 2.1 2 3.4 4 1.8 0.92
pT0 8 2.8 2 3.4 6 2.6 –
pT1 98 34.3 22 37.9 76 33.3 –
pT2 114 39.9 22 37.9 92 40.4 –
pT3 30 10.5 4 6.9 26 11.4 –
pT4 20 7.0 4 6.9 16 7.0 –
Not reported 10 3.5 2 3.4 8 3.5 –
N classification pN0 102 35.7 28 48.3 74 32.5 0.20
pN1 84 29.4 13 22.4 71 31.1 –
pN2 60 21.0 12 20.7 48 21.1 –
pN3 33 11.5 4 6.9 29 12.7 –
Not reported 7 2.4 1 1.7 6 2.6 –
M classification cM0 282 98.6 58 100.0 224 98.2 0.31
cM1 4 1.4 0 0.0 4 1.8 –
ER status Positive 204 71.3 43 74.1 161 70.6 0.62
Negative 71 24.8 14 24.1 57 25.0 –
Not reported 11 3.8 1 1.7 10 4.4 –
PR status Positive 184 64.3 37 63.8 147 64.5 0.89
Negative 86 30.1 17 29.3 69 30.3 –
Not reported 16 5.6 4 6.9 12 5.3 –
Her2/neu status Positive 79 27.6 17 29.3 62 27.2 0.94
Negative 188 65.7 37 63.8 151 66.2 –
K
Strahlenther Onkol
Table 1 Patient, disease, and treatment characteristics stratified by occurrence of treatment interruptions (Continued)
Characteristics Total Treatment interruptions p
Yes No
n % n % n %
Not reported 19 6.6 4 6.9 15 6.6 –
Planning target volume (PTV) Chest wall 150 52.4 27 46.6 123 53.9 0.31
Whole breast 136 47.6 31 53.4 105 46.1 –
Volume of PTV (cm3) 652 71 24.8 9 15.5 62 27.2 0.33
653–872 72 25.2 17 29.3 55 24.1 –
873–1235 71 24.8 16 27.6 55 24.1 –
≥1236 72 25.2 16 27.6 56 24.6 –
Locoregional lymph nodes treated as part
of plan
Yes 149 52.1 25 43.1 124 54.4 0.12
No 137 47.9 33 56.9 104 45.6 –
Boost to the tumor bed Yes 133 46.5 34 58.6 99 43.4 0.04
No 153 53.5 24 41.4 129 56.6 –
Radiotherapy technique TB-IMRT 167 58.4 33 56.9 134 58.8 0.80
3DCRT 119 41.6 25 43.1 94 41.2 –
Fractionation regimen CF 146 51.0 39 67.2 107 46.9 0.01
HF 140 49.0 19 32.8 121 53.1 –
Number of fractions 15 86 30.1 11 19.0 75 32.9 0.01
16–20 45 15.7 8 13.8 37 16.2 –
21–28 70 24.5 11 19.0 59 25.9 –
≥29 85 29.7 28 48.3 57 25.0 –
Chemotherapy Adjuvant 211 73.8 41 70.7 170 74.6 0.58
Neo-adjuvant 61 21.3 15 25.9 46 20.2 –
No chemotherapy 14 4.9 2 3.4 12 5.3 –
Hormone therapy Yes 210 73.4 44 75.9 166 72.8 0.64
No 76 26.6 14 24.1 62 27.2 –
Fatigue (grade CTCAE v4.0) 0 101 35.3 24 41.4 77 33.8 0.51
1 172 60.1 31 53.4 141 61.8 –
2 13 4.5 3 5.2 10 4.4 –
Dermatitis radiation (grade CTCAE v4.0) 0 11 3.8 2 3.4 9 3.9 0.37
1 228 79.7 42 72.4 186 81.6 –
2 44 15.4 13 22.4 31 13.6 –
3 3 1.0 1 1.7 2 0.9 –
Dysphagia (grade CTCAE v4.0) 0 207 72.4 47 81.0 160 70.2 0.26
1 72 25.2 10 17.2 62 27.2 –
2 7 2.4 1 1.7 6 2.6 –
Esophagitis (grade CTCAE v4.0) 0 265 92.7 51 87.9 214 93.9 0.21
1 20 7.0 7 12.1 13 5.7 –
2 1 0.3 0 0.0 1 0.4 –
Cough (grade CTCAE v4.0) 0 266 93.0 54 93.1 212 93.0 0.65
1 17 5.9 4 6.9 13 5.7 –
2 3 1.0 0 0.0 3 1.3 –
Dyspnea (grade CTCAE v4.0) 0 277 96.9 56 96.6 221 96.9 0.83
1 8 2.8 2 3.4 6 2.6 –
2 1 0.3 0 0.0 1 0.4 –
p Values using chi-square testing to compare patient subgroups with and without treatment interruptions, except as indicated
DCIS ductal carcinoma in situ, ER estrogen receptor, PR progesterone receptor, TB-IMRT tangential beam intensity-modulated radiotherapy,
3DCRT three-dimensional conformal radiotherapy, CF conventional fractionation, HF hypofractionation, CTCAE Common Terminology Criteria
for Adverse Events
aUnpaired Student’s t test
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Country of origin Middle East Reference
Asia 1.33 0.43 4.08 0.62
Africa 1.27 0.53 3.05 0.60
Europe/USA 0.30 0.09 1.04 0.06
Age at diagnosis (years) Mean Reference
>Mean 0.92 0.51 1.64 0.77
Body mass index <25 Reference
25–29 1.29 0.55 3.03 0.57
≥30 1.51 0.70 3.25 0.29
Menopausal status Premenopausal Reference
Postmenopausal 1.19 0.67 2.12 0.56
Marital status Married Reference
Single 0.25 0.03 1.93 0.18
Financial status Medical insurance Reference
Cash payer 0.77 0.43 1.36 0.36
Commuting distance to treatment facility (km) 50 Reference
51–100 1.04 0.46 2.36 0.93
>100 1.46 0.54 3.99 0.46
Planning target volume (PTV) Chest wall Reference
Whole breast 0.74 0.42 1.33 0.31
Volume of PTV (cm3) 652 Reference
653–872 0.47 0.19 1.14 0.09
873–1235 0.50 0.20 1.22 0.13
≥1236 0.51 0.21 1.24 0.14
Locoregional lymph nodes treated as part of plan Yes Reference
No 0.64 0.36 1.14 0.13
Boost to the tumor bed Yes Reference
No 1.85 1.03 3.31 0.04
Radiotherapy technique IMRT Reference
3DCRT 0.93 0.52 1.66 0.80
Fractionation regimen CF Reference
HF 2.32 1.27 4.26 <0.01
Number of radiotherapy fractions 15 Reference
16–20 0.68 0.25 1.83 0.44
21–28 0.79 0.32 1.94 0.60
≥29 0.30 0.14 0.65 <0.01
Chemotherapy Adjuvant Reference
Neo-adjuvant 0.74 0.38 1.45 0.38
No chemotherapy 1.45 0.31 6.72 0.64
Hormone therapy Yes Reference
No 1.25 0.64 2.44 0.51
Fatigue (grade CTCAE v4.0) 0 Reference
>0 0.74 0.41 1.33 0.31
Dermatitis radiation (grade CTCAE v4.0) 0 Reference
>0 1.15 0.24 5.48 0.86
Dysphagia (grade CTCAE v4.0) 0 Reference
>0 0.55 0.27 1.13 0.10
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Esophagitis (grade CTCAE v4.0) 0 Reference
>0 2.10 0.81 5.46 0.13
Cough (grade CTCAE v4.0) 0 Reference
>0 0.98 0.32 3.06 0.97
Dyspnea (grade CTCAE v4.0) 0 Reference
>0 1.13 0.23 5.58 0.88
Any acute radiation reaction (grade CTCAE v4.0) 0, 1 Reference
2, 3 1.69 0.87 3.28 0.12
CI confidence interval, IMRT intensity-modulated radiotherapy, 3DCRT three-dimensional conformal radiotherapy, CF conventional fractionation,
HF hypofractionation, CTCAE Common Terminology Criteria for Adverse Events
Table 3 Reason for and length of treatment interruptions stratified by fractionation regimen
Reason for treatment interruptions Total Fractionation regimen p
HF CF
n % n % n %
Public holidays Yes 33 56.9 11 57.9 22 56.4 0.91
No 25 43.1 8 42.1 17 43.6 –
Days, mean (SD) 1.9 (1.8) 1.6 (1.5) 2.1 (2.0) 0.34a
Patient
unwillingness
Yes 23 39.7 8 42.1 15 38.5 0.79
No 35 60.3 11 57.9 24 61.5 –
Days, mean (SD) 0.6 (0.9) 0.5 (0.7) 0.6 (0.9) 0.80a
Machine
breakdown
Yes 8 13.8 1 5.3 7 17.9 0.19
No 50 86.2 18 94.7 32 82.1 –
Days, mean (SD) 0.3 (0.8) 0.1 (0.2) 0.4 (1.0) 0.16a
Radiation
reactions
Yes 4 6.9 0 0 4 10.3 0.15
No 54 93.1 19 100 35 89.7 –
Days, mean (SD) 0.1 (0.3) 0 (0) 0.1 (0.3) 0.16a
Unspecified Yes 1 1.7 1 5.3 0 0 0.15
No 57 98.3 18 94.7 39 100 –
Days, mean (SD) 0.1 (0.4) 0.2 (0.7) 0 (0) 0.15a
Treatment
interruptions
Yes 58 20.3 19 13.6 39 26.7 0.01
No 228 79.7 121 86.4 107 73.3 –
For one reason 47 81.0 17 89.5 30 76.9 0.25
For two reasons 11 19.0 2 10.5 9 23.1 –








0 days 24 41.4 9 47.4 15 38.5 0.68
1 day 15 25.9 6 31.6 9 23.1 –
2 days 9 15.5 1 5.3 8 20.5 –
3 days 5 8.6 1 5.3 4 10.3 –
4 days 3 5.2 1 5.3 2 5.1 –
5 days 2 3.4 1 5.3 1 2.6 –
p Values using chi-square testing to compare patient subgroups treated with HF or CF, except as indicated
CF conventional fractionation, HF hypofractionation
aUnpaired Student’s t test
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fects compared with CF in adjuvant breast cancer radiother-
apy [20–23]. The main motivation for developing protracted
radiotherapy regimens was the benefit to patients and health
services in terms of convenience and cost. Recent breast
cancer studies suggested that HF is also associated with
a significantly lower acute skin reaction rate compared with
CF [7, 24, 25]. Our study revealed another advantage of HF
over CF: a significantly better patient compliance with the
prescribed radiotherapy schedule.
Noncompliance with the prescribed radiotherapy sched-
ule can have multiple deleterious effects. For postoperative
radiotherapy of breast cancer, a prolongation of the over-
all treatment time of more than 1 week has been shown to
decrease the 5-year local control rate by 5% [26]. The man-
agement of the increased number of recurrences may place
additional burden on the health-care system. Disturbances
in the clinical workflow by noncompliant (“no-show”) pa-
tients occupying treatment slots on the linear accelerator
may indirectly cause treatment delays for other patients and
an extension of the work day. Compensation of missed ra-
diotherapy fractions during the working week by additional
treatment on weekends will further increase costs in terms
of time and effort.
In a large study of 2184 patients receiving radiotherapy
with curative intent for various malignancies in an Amer-
ican urban academic cancer center, 20.2% missed mul-
tiple radiotherapy fractions, 17.4% a single radiotherapy
fraction, and 62.4% no radiotherapy fractions. The median
number of missed treatments was 3. Similar to our study,
the statistical analysis identified “prescribed longer radio-
therapy courses” as a statistically significant independent
predictor of noncompliance. The authors suggested that
this finding may provide additional rationale for adopting
shortened radiotherapy schedules as a means of improving
patient adherence to prescribed therapy [27]. Other predic-
tors for noncompliance identified in the previously cited
study were “particular cancer diagnoses,” “low socioeco-
nomic status,” and “treatment during winter months.” “Dis-
tance from the patients’ home to the radiotherapy facility”
[28–30] and “patients from households that lost family in-
come” [31] have been reported as predictors of noncom-
pliance with the prescribed radiotherapy schedule by other
study groups. It is likely that factors influencing compliance
depend to a significant extent on individual circumstances
like the location of the radiotherapy facility, infrastructure
of the region, and socioeconomic status of the population,
and may therefore vary between treatment facilities. How-
ever, in our study CF, which was the longer radiotherapy
schedule compared with HF, was the only significant pre-
dictor of noncompliance on multivariate analysis of 23 fac-
tors.
The limitations of our study should be noted. Owing to
the relatively limited patient number (n = 286), possible
influencing factors may not have reached statistical signifi-
cance. The socioeconomic and psycho-oncological status of
the patients could not be evaluated because of lack of data.
Moreover, owing to the retrospective nature of the study,
a selection bias of patients treated with HF and CF cannot
be excluded with certainty.
Despite all efforts to avoid a prolongation of the pre-
scribed overall treatment time by thorough education of the
patient and compensation of missed radiotherapy fractions
by treatment on weekends, 34 of 286 patients (11.9%) in
our study eventually experienced a moderate prolongation
of the prescribed overall treatment time of 1–5 days. Data
concerning the detrimental effect of treatment interruptions
in adjuvant breast cancer radiotherapy are scarce. However,
a significant decrease in the 5-year local control rate af-
ter treatment interruptions of more than 1 week has been
reported [26].
Conclusion
A significant proportion of breast cancer patients in our
study experienced treatment interruptions. Compliance with
the prescribed radiotherapy schedule was significantly bet-
ter for patients treated with HF than for those treated with
CF. The data suggest that the better compliance is basi-
cally related to the shorter overall treatment time of HF
(3–4 weeks) compared with CF (5–6.5 weeks). This finding
may add to the treatment decision in favor of HF in par-
ticular in situations with expected lower compliance with
longer radiotherapy schedules.
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